{"id":"W2094188569","doi":"10.1038/bjc.2011.182","title":"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Pharmacodynamics; Pharmacokinetics; Internal medicine; Nausea; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Gastroenterology; Cancer; Pharmacology; Colorectal cancer; Chemotherapy; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001708729,0.0001556354,0.0004152869,0.000120687,0.00005095666,0.00001704594,0.00007338519,0.00001265647,0.00002259186],"category_scores_gemma":[0.00002272147,0.0001073676,0.00002834558,0.0002117694,0.00007688422,0.0001514067,0.00002615093,0.0001740281,5.508275e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001606464,"about_ca_system_score_gemma":0.00008366285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003809927,"about_ca_topic_score_gemma":0.004121072,"domain_scores_codex":[0.998813,0.00005933211,0.0004487075,0.0001571676,0.000343522,0.0001782094],"domain_scores_gemma":[0.9990017,0.0000361006,0.0003415523,0.00006583237,0.0004848746,0.00006990553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02925329,0.003780385,0.695918,0.0000264074,0.0001192654,0.0002456572,0.002640575,0.00009295354,0.0005462819,4.757439e-7,0.000007006185,0.2673697],"study_design_scores_gemma":[0.06482463,0.01839233,0.9138632,0.001057848,0.0001247722,0.0001648218,0.0006840035,0.0003478783,0.0004125192,0.000004123988,0.00002082912,0.0001029799],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974793,0.001027362,0.00006895479,0.0001057527,0.00003585454,0.001196501,0.00002869137,0.000003907584,0.00005367344],"genre_scores_gemma":[0.9982665,0.001066528,0.0004997918,0.00006772282,0.00002081334,0.00003595268,0.000003452981,0.00001948937,0.00001971889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2672667,"threshold_uncertainty_score":0.4378322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01573615130210611,"score_gpt":0.2929622665639344,"score_spread":0.2772261152618283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}